Literature DB >> 8140046

Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation.

E A Mueller1, J M Kovarik, J B van Bree, J Grevel, P W Lücker, K Kutz.   

Abstract

The influence of a fat-rich meal on the pharmacokinetics of cyclosporine from a new oral formulation (Sandimmune Neoral) was compared in a randomized, four-way crossover study to the currently marketed formulation (Sandimmune) in 24 healthy male volunteers. Single oral doses of 300 mg Sandimmune and 180 mg Sandimmune Neoral were each administered once under fasting conditions and once 30 min after starting a high-fat meal. Serial blood samples were obtained over a 48-hr period after each administration, and whole-blood cyclosporine concentrations were determined by a specific monoclonal radioimmunoassay method. Food had a marked effect on cyclosporine absorption from Sandimmune manifested by a nearly doubled time to reach the peak concentration and a 37% increase in the area under the curve. This was associated with significant elevations in subsequent whole-blood cyclosporine concentrations compared to the fasting administration. For Sandimmune Neoral the influence was less pronounced. The maximum concentration was decreased by 26%, without a relevant change in the time to reach the peak; the area under the curve showed a slight reduction of 15%. The relatively minor influence of a fat-rich meal on the absorption of cyclosporine from Sandimmune Neoral is advantageous when individualizing a dosage regimen under clinical and outpatient administration conditions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8140046     DOI: 10.1023/a:1018922517162

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  The effect of meal composition on cyclosporine absorption.

Authors:  N Honcharik; R W Yatscoff; J R Jeffery; D N Rush
Journal:  Transplantation       Date:  1991-12       Impact factor: 4.939

2.  Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.

Authors:  S K Gupta; R C Manfro; S J Tomlanovich; J G Gambertoglio; M R Garovoy; L Z Benet
Journal:  J Clin Pharmacol       Date:  1990-07       Impact factor: 3.126

3.  High-fat meals increase the clearance of cyclosporine.

Authors:  S K Gupta; L Z Benet
Journal:  Pharm Res       Date:  1990-01       Impact factor: 4.200

4.  The effect of food and bile acid administration on the relative bioavailability of cyclosporin.

Authors:  A Lindholm; S Henricsson; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

5.  Specific 3H radioimmunoassay with a monoclonal antibody for monitoring cyclosporine in blood.

Authors:  P E Ball; H Munzer; H P Keller; E Abisch; J Rosenthaler
Journal:  Clin Chem       Date:  1988-02       Impact factor: 8.327

6.  Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects.

Authors:  J Grevel; E Nüesch; E Abisch; K Kutz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 7.  Influence of food and diet on gastrointestinal drug absorption: a review.

Authors:  P G Welling
Journal:  J Pharmacokinet Biopharm       Date:  1977-08

8.  The effect of food on cyclosporine absorption.

Authors:  R J Ptachcinski; R Venkataramanan; J T Rosenthal; G J Burckart; R J Taylor; T R Hakala
Journal:  Transplantation       Date:  1985-08       Impact factor: 4.939

Review 9.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

10.  Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism.

Authors:  W M Awni; B L Kasiske; K Heim-Duthoy; K V Rao
Journal:  Clin Pharmacol Ther       Date:  1989-01       Impact factor: 6.875

View more
  28 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.

Authors:  Joseph M Custodio; Chi-Yuan Wu; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2007-11-28       Impact factor: 15.470

Review 3.  Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance.

Authors:  Angel Tan; Shasha Rao; Clive A Prestidge
Journal:  Pharm Res       Date:  2013-06-18       Impact factor: 4.200

Review 4.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 5.  Safety aspects of cyclosporin in rheumatoid arthritis.

Authors:  B A Dijkmans
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 6.  International consensus recommendations on cyclosporin use in rheumatoid arthritis.

Authors:  P Tugwell
Journal:  Drugs       Date:  1995       Impact factor: 9.546

7.  Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats.

Authors:  Mari Jiko; Ikuko Yano; Hiroko Wakasugi; Hideyuki Saito; Ken-ichi Inui
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

8.  Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.

Authors:  Franziska Schädeli; Hans-Peter Marti; Felix J Frey; Dominik E Uehlinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease.

Authors:  M Latteri; G Angeloni; N G Silveri; R Manna; G Gasbarrini; P Navarra
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

10.  Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol.

Authors:  Anna Elgart; Irina Cherniakov; Yanir Aldouby; Abraham J Domb; Amnon Hoffman
Journal:  Pharm Res       Date:  2013-05-18       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.